AbbVie Inc. targets $38B in Skyrizi and Rinvoq sales by 2030, a 3% dividend yield, and 7.7% EPS growth via acquisitions.
AbbVie Inc. stays a Strong Buy after a Q4 2025 earnings beat led by HUMIRA, plus growth in immunology and neuroscience. Click ...
Feb 4 (Reuters) - AbbVie forecast 2026 profit above Wall Street estimates on Wednesday after posting a fourth-quarter results beat, fueled by strong demand for newer immunology drugs Skyrizi and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results